Skip to main content

SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial

Tipranks - Tipranks - Tue May 6, 2025

Truist Financial analyst Joon Lee maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today. The company’s shares closed last Friday at $7.30.

Protect Your Portfolio Against Market Uncertainty

According to TipRanks, Lee is a 5-star analyst with an average return of 21.5% and a 50.95% success rate. Lee covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Corcept Therapeutics, and Viking Therapeutics.

In addition to Truist Financial, SAGE Therapeutics also received a Hold from Needham’s Ami Fadia in a report issued on April 30. However, on the same day, Scotiabank maintained a Buy rating on SAGE Therapeutics (NASDAQ: SAGE).

See the top stocks recommended by analysts >>

The company has a one-year high of $14.31 and a one-year low of $4.62. Currently, SAGE Therapeutics has an average volume of 1.33M.

Read More on SAGE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).